MXPA05002249A - Antagonistas selectivos del receptor d1/d5 para el tratamiento de obesidad y trastornos del sistema nervioso central. - Google Patents

Antagonistas selectivos del receptor d1/d5 para el tratamiento de obesidad y trastornos del sistema nervioso central.

Info

Publication number
MXPA05002249A
MXPA05002249A MXPA05002249A MXPA05002249A MXPA05002249A MX PA05002249 A MXPA05002249 A MX PA05002249A MX PA05002249 A MXPA05002249 A MX PA05002249A MX PA05002249 A MXPA05002249 A MX PA05002249A MX PA05002249 A MXPA05002249 A MX PA05002249A
Authority
MX
Mexico
Prior art keywords
compound
alkyl
hydrogen
substituted
aryl
Prior art date
Application number
MXPA05002249A
Other languages
English (en)
Spanish (es)
Inventor
Thavalakulam K Sasikumar
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MXPA05002249A publication Critical patent/MXPA05002249A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA05002249A 2002-08-29 2003-08-27 Antagonistas selectivos del receptor d1/d5 para el tratamiento de obesidad y trastornos del sistema nervioso central. MXPA05002249A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40685602P 2002-08-29 2002-08-29
PCT/US2003/026878 WO2004020442A1 (en) 2002-08-29 2003-08-27 Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders

Publications (1)

Publication Number Publication Date
MXPA05002249A true MXPA05002249A (es) 2005-06-08

Family

ID=31978370

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05002249A MXPA05002249A (es) 2002-08-29 2003-08-27 Antagonistas selectivos del receptor d1/d5 para el tratamiento de obesidad y trastornos del sistema nervioso central.

Country Status (11)

Country Link
US (1) US7211574B2 (enExample)
EP (1) EP1537115B1 (enExample)
JP (1) JP4555685B2 (enExample)
CN (1) CN1688584A (enExample)
AT (1) ATE396996T1 (enExample)
AU (1) AU2003262926A1 (enExample)
CA (1) CA2495879C (enExample)
DE (1) DE60321354D1 (enExample)
ES (1) ES2308016T3 (enExample)
MX (1) MXPA05002249A (enExample)
WO (1) WO2004020442A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1823059A (zh) * 2003-05-22 2006-08-23 先灵公司 作为治疗肥胖和CNS疾病的选择性D<sub>1</sub>/D<sub>5</sub>受体拮抗剂的5－H－苯并[D]萘并[2,1－B]氮杂䓬衍生物
WO2025194153A1 (en) 2024-03-15 2025-09-18 Emalex Biosciences, Inc. Pharmaceutical dosage forms and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973586A (en) * 1986-01-16 1990-11-27 Schering Corporation Fused benzazepines, compositions of, and medical use thereof
WO1987004430A2 (en) * 1986-01-16 1987-07-30 Schering Corporation Fused benzazepines
ATE78467T1 (de) * 1987-07-15 1992-08-15 Schering Corp Kondensierte benzazepine.
DK325188D0 (da) * 1988-06-15 1988-06-15 Novo Industri As Hidtil ukendte benzazepinderivater
WO2003006466A1 (en) * 2001-07-13 2003-01-23 Pharmacia & Upjohn Company Hexahydroazepino (4, 5-g) indoles and indolines as 5-ht receptor ligands

Also Published As

Publication number Publication date
JP4555685B2 (ja) 2010-10-06
AU2003262926A1 (en) 2004-03-19
CA2495879C (en) 2011-04-26
JP2006501244A (ja) 2006-01-12
CN1688584A (zh) 2005-10-26
DE60321354D1 (de) 2008-07-10
CA2495879A1 (en) 2004-03-11
US7211574B2 (en) 2007-05-01
US20040058906A1 (en) 2004-03-25
WO2004020442A1 (en) 2004-03-11
ES2308016T3 (es) 2008-12-01
EP1537115A1 (en) 2005-06-08
EP1537115B1 (en) 2008-05-28
ATE396996T1 (de) 2008-06-15

Similar Documents

Publication Publication Date Title
EP1453835B1 (en) Adenosine a 2a receptor antagonists
EP3416639B1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m1
EP3703680B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
JP2023554282A (ja) 置換ピペリジノ化合物及び関連する治療方法
WO2005040135A1 (ja) 抗ストレス薬およびその医薬用途
JP2010155848A (ja) 肥満治療用のｍｃｈアンタゴニスト
EP3390374A1 (en) Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
EP3534901B1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
EP3697781B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
JP2011516397A (ja) 電位依存性ナトリウムチャネルのモジュレーターとしてのプロリンアミド誘導体
EP3558309B1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
US20230044216A1 (en) Aldehyde and ketone derivatives of psilocybin and methods of using
EP1648882A1 (en) 3-fluoro-piperidines as nmda/nr2b antagonists
EP3672950A1 (en) Novel heterocyclic compounds as modulators of mglur7
MXPA06002201A (es) Derivados bencimidazol 2-substituidos como antagonistas selectivos del receptor de la hormona concentradora de melanina, para el tratamiento de la obesidad y desordenes relacionados.
HUP0003118A2 (hu) 2,7-Szubsztituált oktahidro-1H-pirido-[1,2-a]pirazin-származékok alkalmazása gyógyszerkészítmények előállítására
CA2495879C (en) Selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders
EP1646623A2 (en) 5-h-benzo[d]naphth[2,1-b]azepine derivative as selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders
JP2006526021A5 (enExample)
EP2958919B1 (en) Dihydropteridinones i
JP2006501244A5 (enExample)
EP4291552B1 (en) Modulators of complex i
EP0785195A1 (en) Piperidine or tetrahydropyridine derivatives having affinity for the serotonin 5-HTIA receptor
TW200413380A (en) Pyrrolo[1, 2-B]pyridazine compounds and their uses
WO2007021803A1 (en) Compounds for the treatment of inflammatory disorders

Legal Events

Date Code Title Description
FG Grant or registration